<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Gene test interpretation: Lynch syndrome genes (&lt;i&gt;MLH1&lt;/i&gt;, &lt;i&gt;MSH2&lt;/i&gt;, &lt;i&gt;MSH6&lt;/i&gt;, &lt;i&gt;PMS2&lt;/i&gt;, &lt;i&gt;EPCAM&lt;/i&gt;)</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Gene test interpretation: Lynch syndrome genes (<i>MLH1</i>, <i>MSH2</i>, <i>MSH6</i>, <i>PMS2</i>, <i>EPCAM</i>)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Gene test interpretation: Lynch syndrome genes (<i>MLH1</i>, <i>MSH2</i>, <i>MSH6</i>, <i>PMS2</i>, <i>EPCAM</i>)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel C Chung, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Linda H Rodgers, MGC, CGC</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Barbara Goff, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anne Slavotinek, MBBS, PhD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shilpa Grover, MD, MPH, AGAF</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alana Chakrabarti, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 08, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H785550992"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>This monograph summarizes the interpretation of germline testing for a Lynch syndrome gene. It does <strong>not</strong> discuss indications for testing and is not intended to replace clinical judgment in the decision to test or in the clinical care of the individual who was tested. It also does not discuss testing of tumors for DNA mismatch repair (MMR) or microsatellite instability (MSI). These subjects are discussed separately [<a href="#rid1">1</a>]. (See <a class="local">'UpToDate topics'</a> below.)</p><p class="headingAnchor" id="H859092212"><span class="h1">OVERVIEW</span></p><p class="headingAnchor" id="H2704967017"><span class="h2">How to read the report</span><span class="headingEndMark"> — </span>An approach to reviewing a genetic test report is summarized in the checklist  (<a class="graphic graphic_table graphicRef122437" href="/z/d/graphic/122437.html" rel="external">table 1</a>).</p><p>Testing involves two steps: determining the genotype and interpreting the pathogenicity of the variant(s).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genotype</strong> – Identifies the variant(s). Should be repeated in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory, or comparable accreditation body in other jurisdictions, if the results were obtained by direct-to-consumer testing or a research study and would impact clinical care (eg, positive finding; negative finding in an individual with a suspected colorectal cancer syndrome based on personal or family history). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interpretation</strong> – Determines pathogenicity of the variants identified. May require updating. (See <a class="local">'Classification of variants'</a> below.)</p><p></p><p>The table provides a glossary of terms in genetic testing reports  (<a class="graphic graphic_table graphicRef122429" href="/z/d/graphic/122429.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H4010455760"><span class="h2">Classification of variants</span><span class="headingEndMark"> — </span>It is important to review which gene(s) were analyzed and which variants in those genes were tested, as some tests use comprehensive sequencing whereas others only screen for selected genes and/or selected variants. </p><p>The pathogenicity of each variant is classified by the testing laboratory into one of five categories based on information available to them at the time  (<a class="graphic graphic_table graphicRef122646" href="/z/d/graphic/122646.html" rel="external">table 3</a>) [<a href="#rid2">2</a>]. </p><p>The classification for many variants continues to be updated, especially for variants of uncertain significance (VUS), as more evidence regarding pathogenicity (or lack thereof) becomes available. The uncertainty reflects the current state of information and knowledge available, rather than the accuracy of genotyping or the likelihood of disease. </p><p>If there is concern about the classification, such as for a VUS, obtain an updated interpretation periodically (eg, annually). This can be done by checking a database such as <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fclinvar%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4trzGy12ipcVcj41059JRLkL3&amp;TOPIC_ID=121915" target="_blank">ClinVar</a>, contacting the laboratory, or consulting a clinical geneticist, genetic counselor, or other specialist (see <a class="local">'Locating an expert'</a> below); there is no gold standard approach. Some laboratories routinely provide updates and others require a request. Likely benign and benign variants are typically not reported (or are reported as negative). Many VUSs are reclassified as benign. </p><p class="headingAnchor" id="H2934928128"><span class="h2">Disease associations</span><span class="headingEndMark"> — </span>DNA mismatch repair (MMR) is a normal component of genome maintenance. Lynch syndrome (previously called hereditary nonpolyposis colorectal cancer [HNPCC]) is a cancer predisposition syndrome caused by a germline mutation that impairs MMR. </p><p>Lynch syndrome genes include:</p><p class="bulletIndent1"><span class="glyph">●</span><em>MLH1</em></p><p class="bulletIndent1"><span class="glyph">●</span><em>MSH2</em></p><p class="bulletIndent1"><span class="glyph">●</span><em>MSH6</em></p><p class="bulletIndent1"><span class="glyph">●</span><em>PMS2</em></p><p class="bulletIndent1"><span class="glyph">●</span><em>EPCAM</em> (gene upstream of <em>MSH2</em> that affects <em>MSH2 </em>transcription)</p><p></p><p>Pathogenic and likely pathogenic variants in Lynch syndrome genes are associated with increased risk for several cancers [<a href="#rid3">3</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Colorectal </p><p class="bulletIndent1"><span class="glyph">●</span>Endometrial </p><p class="bulletIndent1"><span class="glyph">●</span>Ovarian </p><p class="bulletIndent1"><span class="glyph">●</span>Urinary tract (more frequent with pathogenic or likely pathogenic variants in <em>MSH2</em>, especially males)</p><p class="bulletIndent1"><span class="glyph">●</span>Gastric and small bowel </p><p class="bulletIndent1"><span class="glyph">●</span>Hepatobiliary and pancreatic </p><p class="bulletIndent1"><span class="glyph">●</span>Brain (gliomas) </p><p class="bulletIndent1"><span class="glyph">●</span>Skin (sebaceous) </p><p></p><p>Selected cancer risks are summarized in the table  (<a class="graphic graphic_table graphicRef52285" href="/z/d/graphic/52285.html" rel="external">table 4</a>). </p><p>Colorectal cancers in individuals with a pathogenic or likely pathogenic variant in a Lynch syndrome gene will have deficient mismatch repair (dMMR) and high levels of microsatellite instability (MSI-H).</p><p>Lynch syndrome is autosomal dominant with incomplete penetrance  (<a class="graphic graphic_table graphicRef122429" href="/z/d/graphic/122429.html" rel="external">table 2</a>). A pathogenic variant inherited from one parent is sufficient to increase risk for the associated cancers, but not all individuals with the variant will develop cancer.</p><p>Rarely, two pathogenic variants (inherited from both parents) may co-occur, leading to constitutional MMR deficiency (CMMRD), a syndrome of hematologic cancers, brain tumors, Lynch syndrome cancers in childhood, and a neurofibromatosis 1-like phenotype. (See  <a class="medical medical_review" href="/z/d/html/2605.html" rel="external">"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Clinical manifestations and diagnosis", section on 'Differential diagnosis'</a>.)</p><p class="headingAnchor" id="H4045155816"><span class="h1">PEOPLE WITHOUT CANCER</span></p><p class="headingAnchor" id="H2984178190"><span class="h2">Implications of a pathogenic or likely pathogenic variant</span><span class="headingEndMark"> — </span>Counseling and cancer risk reduction is the same regardless of whether a variant is classified as pathogenic or likely pathogenic. Absence of a family history does not alter the increased risk conferred by such a variant. Discussion should include the range of cancer risks, possible interventions for surveillance or risk reduction, and implications for at-risk family members. The discussion is individualized based on the tested individual's age. </p><p>Counseling may require additional visits or referral to a clinical geneticist, genetic counselor, or specialist. Genetic test results are rarely an emergency; most management decisions can be deferred until questions have been answered.</p><p>Adherence to the National Comprehensive Cancer Network (NCCN) recommendations for surveillance and risk reduction is generally appropriate [<a href="#rid3">3</a>]. Some features of the family history may warrant additional surveillance (eg, screening at an earlier age, screening for other cancers common to the family). </p><p>Several evaluations and interventions are available  (<a class="graphic graphic_table graphicRef122460" href="/z/d/graphic/122460.html" rel="external">table 5</a>). The following represent general recommendations; each individual should meet with a specialist and use shared decision-making to determine their personalized management  (<a class="graphic graphic_algorithm graphicRef122845" href="/z/d/graphic/122845.html" rel="external">algorithm 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Colorectal cancer:</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Colonoscopy starting at age 20 to 25 years (earlier for some based on family history); repeated every one to two years.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Discussion of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> for chemoprevention. Regular use may reduce the long-term incidence of colorectal cancer, but the optimal dose is unknown. The decision is individualized; many will choose to take low-dose aspirin. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastric cancer:</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Upper endoscopy with visualization of the duodenum starting at age 30 to 35 years; repeated every two to four years.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><em>Helicobacter pylori</em> testing and treatment if positive.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endometrial and ovarian cancers:</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Education regarding symptoms and importance of evaluating them:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Endometrial cancer symptoms – Abnormal uterine bleeding, postmenopausal bleeding.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Ovarian cancer symptoms – Pelvic/abdominal pain, bloating, increased abdominal girth, early satiety, urinary changes.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Discussion of risk-reducing surgery:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Hysterectomy and bilateral salpingo-oophorectomy (BSO) are advised after completion of childbearing.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Small retrospective series suggest significant risk reduction. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Risks include perioperative complications and premature menopause in premenopausal women.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Discussion of increased surveillance for those who have not undergone risk-reducing surgery, acknowledging lack of evidence for a reduction in mortality:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Endometrial biopsies for those who have not undergone hysterectomy.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Transvaginal ultrasounds and serum CA-125 assays for those who have not undergone BSO.</p><p></p><p class="bulletIndent2">Surveillance is typically started at age 30 to 35 (or 5 to 10 years prior to the earliest age of endometrial cancer in the family). The optimal frequency of these evaluations is unknown, and the recommended intervals vary by the type of surveillance test being used.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Consideration of hormonal chemoprevention with an oral contraceptive for those who are premenopausal and have not had risk-reducing surgery.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Urothelial cancer:</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Consideration of annual urinalysis starting at age 30 to 35, especially for individuals with an <em>MSH2</em> variant, males, and those with a family history of urothelial cancer.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Skin cancer:</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Skin examination every one to three years.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prostate cancer:</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In <em>MSH2</em> and <em>MSH6</em> carriers, discussion of prostate cancer screening by prostate-specific antigen test at age 40 and follow-up in a high-risk cancer screening clinic.</p><p></p><p>Individuals with a strongly positive family history for a particular type of cancer (eg, pancreatic cancer) may choose to undergo more aggressive surveillance. Conversely, it may be appropriate for individuals with a pathogenic variant in a lower risk gene (eg, <em>PMS2</em>) to begin surveillance at later ages or with less frequency.</p><p>Details and supporting evidence are presented separately. (See  <a class="medical medical_review" href="/z/d/html/15804.html" rel="external">"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Cancer screening and management"</a> and  <a class="medical medical_review" href="/z/d/html/3224.html" rel="external">"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and prevention of endometrial and ovarian cancer"</a> and  <a class="medical medical_review" href="/z/d/html/112282.html" rel="external">"Genetic risk factors for prostate cancer", section on 'Lynch syndrome and mismatch repair deficiency'</a> and  <a class="medical medical_review" href="/z/d/html/112282.html" rel="external">"Genetic risk factors for prostate cancer", section on 'IMPACT study'</a>.)</p><p class="headingAnchor" id="H4092102478"><span class="h2">Implications of a negative test</span><span class="headingEndMark"> — </span>Negative testing means that specific pathogenic variants tested were not found  (<a class="graphic graphic_algorithm graphicRef122845" href="/z/d/graphic/122845.html" rel="external">algorithm 1</a>). </p><p class="bulletIndent1"><span class="glyph">●</span>If a pathogenic variant has been identified in a family and the tested individual does not have that variant, they can be reassured, with the caveats outlined above (see <a class="local">'How to read the report'</a> above). For some individuals, risk may be increased by other factors (genetic and/or acquired), and additional testing with a multigene panel may be appropriate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If a pathogenic variant has not been identified in a family and the tested individual does not have a pathogenic variant, surveillance is based on family history<em> </em>and other risk factors. Referral to a clinical geneticist, oncologist, or genetic counselor may be helpful if there is a strong family history of cancer. (See  <a class="medical medical_review" href="/z/d/html/2606.html" rel="external">"Epidemiology and risk factors for colorectal cancer"</a> and <a class="local">'Locating an expert'</a> below.)</p><p></p><p class="headingAnchor" id="H1046791515"><span class="h2">Implications of a VUS</span><span class="headingEndMark"> — </span>Individuals who have a variant of uncertain significance (VUS) should be managed based on their personal and family history and not the VUS  (<a class="graphic graphic_algorithm graphicRef122845" href="/z/d/graphic/122845.html" rel="external">algorithm 1</a>). Pathogenicity may be revised, and updated information should be sought periodically. (See <a class="local">'Classification of variants'</a> above.) </p><p class="headingAnchor" id="H4240873109"><span class="h1">PEOPLE WITH CANCER</span><span class="headingEndMark"> — </span>The implications of genetic testing results should be discussed with the individual's oncologist or surgeon. Referral to a specialist in hereditary colorectal cancer syndromes may be appropriate. </p><p>Considerations for a pathogenic or likely pathogenic variant in a Lynch syndrome gene include:</p><p class="bulletIndent1"><span class="glyph">●</span>More extensive colorectal cancer surgery.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prophylactic hysterectomy and risk-reducing bilateral salpingo-oophorectomy (rrBSO) for women at the time of colorectal cancer resection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ongoing surveillance for those who have less extensive surgery (eg, annual colonoscopy).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Option of cancer immunotherapy (eg, a programmed cell death-1 [PD-1] inhibitor, with or without a CTLA-4 inhibitor).</p><p></p><p>Details are presented separately. (See <a class="local">'UpToDate topics'</a> below.)</p><p>Counseling and testing of at-risk family members should be discussed. (See <a class="local">'Considerations for the family'</a> below.)</p><p>For individuals with a negative test or a variant of uncertain significance (VUS) for whom there is concern about a genetic cause, additional genetic testing may be appropriate; this may be discussed with a clinical geneticist, genetic counselor, the primary oncologist, or other specialist. (See <a class="local">'Implications of a VUS'</a> above.)</p><p class="headingAnchor" id="H1872408305"><span class="h1">CONSIDERATIONS FOR THE FAMILY</span></p><p class="headingAnchor" id="H45339875"><span class="h2">Reproductive counseling</span><span class="headingEndMark"> — </span>Reproductive counseling (ideally done prior to conception) is appropriate for individuals with a pathogenic or likely pathogenic variant who are considering childbearing. </p><p>Some may opt for donor gametes or in vitro fertilization (IVF) with preimplantation genetic testing (PGT). (See  <a class="medical medical_review" href="/z/d/html/6783.html" rel="external">"Preimplantation genetic testing", section on 'Patients known to be at increased risk of offspring with a specific medically actionable condition'</a>.) </p><p class="headingAnchor" id="H1624585140"><span class="h2">At-risk relatives</span><span class="headingEndMark"> — </span>Individuals with a pathogenic variant or likely pathogenic variant should discuss this with their at-risk relatives and inform them about the importance of genetic counseling and/or possible testing.</p><p class="bulletIndent1"><span class="glyph">●</span>The risk of having inherited the variant is approximately 50 percent for first-degree relatives. Other at-risk relatives may include aunts, uncles, nieces, nephews, and cousins. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Usually the variant segregates on the side of the family with Lynch syndrome cancers; however, if possible, it is recommended to test an affected parent or other relative with a Lynch syndrome cancer to confirm which side of the family is at risk.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Most Lynch syndrome cancers do not develop until adulthood. Deferral of testing until age 18 or older is appropriate to allow informed consent. (See  <a class="medical medical_review" href="/z/d/html/2901.html" rel="external">"Genetic testing", section on 'Ethical, legal, and psychosocial issues'</a>.)</p><p></p><p class="headingAnchor" id="H4001135738"><span class="h1">RESOURCES</span></p><p class="headingAnchor" id="H1833798585"><span class="h2">UpToDate topics</span></p><p class="bulletIndent1"><span class="glyph">●</span>Cancer risks – (See  <a class="medical medical_review" href="/z/d/html/15804.html" rel="external">"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Cancer screening and management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Testing and diagnosis – (See  <a class="medical medical_review" href="/z/d/html/2605.html" rel="external">"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Colorectal cancer screening – (See  <a class="medical medical_review" href="/z/d/html/15804.html" rel="external">"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Cancer screening and management", section on 'Screening for Lynch-associated cancers'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Endometrial cancer screening – (See  <a class="medical medical_review" href="/z/d/html/3224.html" rel="external">"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and prevention of endometrial and ovarian cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cancer risk reduction – (See  <a class="medical medical_review" href="/z/d/html/15804.html" rel="external">"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Cancer screening and management", section on 'Management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Colorectal cancer treatment </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>General principles – (See  <a class="medical medical_review" href="/z/d/html/15804.html" rel="external">"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Cancer screening and management", section on 'Management'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Adjuvant therapy – (See  <a class="medical medical_review" href="/z/d/html/15256.html" rel="external">"Adjuvant therapy for resected stage II colon cancer"</a> and  <a class="medical medical_review" href="/z/d/html/2471.html" rel="external">"Adjuvant therapy for resected stage III (node-positive) colon cancer"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Metastatic disease – (See  <a class="medical medical_review" href="/z/d/html/15802.html" rel="external">"Systemic therapy for metastatic colorectal cancer: General principles"</a> and  <a class="medical medical_review" href="/z/d/html/2503.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Rectal cancer – (See  <a class="medical medical_review" href="/z/d/html/106743.html" rel="external">"Overview of the management of rectal adenocarcinoma"</a> and  <a class="medical medical_review" href="/z/d/html/2468.html" rel="external">"Neoadjuvant therapy for rectal adenocarcinoma"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Immunotherapy – (See  <a class="medical medical_review" href="/z/d/html/120646.html" rel="external">"Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors"</a>.)</p><p></p><p class="headingAnchor" id="H2968925731"><span class="h2">Locating an expert</span></p><p class="bulletIndent1"><span class="glyph">●</span>Clinical geneticists – American College of Genetics and Genomics (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinics.acmg.net%2F&amp;token=nbsXe3i4qfUea5RCPRHtOdEP95SDL7NSm8b1jbZpdwjlW9H1hfmmq%2FTbAbE64qhV&amp;TOPIC_ID=121915" target="_blank">ACMG</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Genetic counselors – National Society of Genetic Counselors (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffindageneticcounselor.nsgc.org%2F&amp;token=AU2cQkyAZolWVu502Wzur%2F2gjdsB%2FYlqRYYyoKtNflwwaDFffULns7AVKZBF0Vtm&amp;TOPIC_ID=121915" target="_blank">NSGC</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>National Institutes of Health (NIH) Cancer Genetics <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cancer.gov%2Fabout-cancer%2Fcauses-prevention%2Fgenetics%2Fdirectory&amp;token=j%2Fp%2BIZfImoJgnd%2Fk4T5MAbDlZmLADFk1VrVOJqDdPzf1mGWFw3YadpFlBYSMxNKDeExYMR0QNQoNISFKbh7RPtm%2BfHLonSi2ZDCqhRzTq0w%3D&amp;TOPIC_ID=121915" target="_blank">Services Directory</a> </p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.</li><li><a class="nounderline abstract_t">Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17:405.</a></li><li class="breakAll">https://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf (Accessed on August 22, 2019).</li></ol></div><div id="topicVersionRevision">Topic 121915 Version 18.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25741868" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
